Health Trials

About this trial

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Eligibility criteria

Qualifiers

Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)

Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.

Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)

Disqualifiers

Lack of written informed consent.

Trial design

Treatments tested in this trial

  • PANcreatic cancer Exosome Early detectiON (PANXEON)

Treatment groups

2,000 Participants
are divided into 4 treatment groups

Locations

11
Japan
Nagoya University Nagoya Japan
South Korea
Asan Medical Center Seoul South Korea
United States
Arizona
Translational Genomics Research Institute85004, Phoenix United States
Honorhealth85258, Scottsdale United States

Sponsors and collaborators

City of Hope Medical Center

Lead sponsor

Source ClinicalTrials.gov